Business Wire

SOFINNOVA-PARTNERS

4.1.2024 17:01:29 CET | Business Wire | Press release

Share
Sofinnova Partners Brings in Dr. Joshua Makower, Stanford Biodesign Co-Founder, as Venture Partner

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced that Dr. Joshua Makower, co-founder and director of the Stanford Byers Center for Biodesign, has joined Sofinnova as an advisory Venture Partner.

Dr. Makower co-founded Stanford Biodesign with Dr. Paul Yock 23 years ago, creating the core curriculum — now known as "The Biodesign Process" — that has been used at Stanford and around the world to train hundreds of thousands of students and industry leaders who have gone on to advance medical innovation and improve the lives of countless patients.

He is the Founder & Executive Chairman of ExploraMed, a medical device incubator that has created eleven companies since 1995. Highlights from the ExploraMed portfolio include NeoTract, maker of a device and procedure to treat an enlarged prostate that was acquired by Teleflex; Acclarent, a creator of devices for minimally invasive sinus surgeries, which was bought by J&J; and TransVascular, a pioneer in transvascular procedures, acquired by Medtronic.

Dr. Makower was a longtime partner in NEA’s healthcare practice, advising the healthcare team and medtech/healthtech investing practice. He sits on the boards of six companies and holds more than 300 patents and patent applications.

Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, said: “We are incredibly fortunate to have Josh on board. For more than 28 years, he has played a key role in the evolution of the medical devices field — and in the education of those who wish to create technology that will make patients' lives easier."

Dr. Makower said: "I’m really looking forward to partnering with the team at Sofinnova Partners, having observed and respected the firm’s leadership and vision in the medical device space for many years. This is a firm that consistently leads investments in ventures that tackle important unsolved clinical needs with great success.”

Anne Osdoit, Partner at Sofinnova Partners, and a key member of the firm’s medtech accelerator, MD Start, said: "Josh literally wrote the book on designing biomedical technology. He is a giant in the field, and will lend us a formidable presence in the United States as we expand our medical devices incubation strategy globally.”

Dr. Makower has an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT. He is also a Member of the National Academy of Engineering, a Fellow of The National Academy of Inventors and The American Institute for Medical and Biological Engineering and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.

Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240104955859/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release

QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye